Clinical Trials Browser

Terminated × INDUSTRY × mocetinostat × Clear all

NCT02954991 2024-04-22

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Phase 2 Terminated

161 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT02805660 2021-04-06

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

Phase 1/2 Terminated

83 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00358982 2015-07-03

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 2 Terminated

Hodgkin Disease, Recurrence

NCT00374296 2015-07-01

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

Phase 2 Terminated

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00543582 2015-07-01

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Phase 2 Terminated

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00666497 2015-05-08

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Phase 2 Terminated

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00511576 2015-01-08

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Phase 1 Terminated

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms, Stomach Neoplasms